Novel bioadhesive patch-type system for photodynamic vulvodynia therapy after delivery of 5-aminolevulinic acid - Preliminary evaluation

A. A. Zawislak, P. A. McCarron, W. G. McCluggage, R. F. Donnelly, J. H. Price, H. R. McClelland, A. D. Woolfson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

OBJECTIVE: To assess the applicability of photodynamic therapy (PDT) in the management of vulvodynia whereby a novel, patch-type system, loaded with 5-aminolevulinic acid (ALA), was used to administer PDT to vulvar regions displaying the characteristics of vulvodynia. STUDY DESIGN: Eleven patients underwent PDT using a bioadhesive patch to deliver ALA over 4 hours. A nonlaser light source delivered 100 1 cm(-2) to the target area using red light of 630 nm. Fluorescence of protoporphyrin IX was observed under ultraviolet light illumination, with no significant difference found between that produced after the first and second applications of the patch. RESULTS: There was a significant reduction (p= 0.0077) in overall symptoms after completion of treatment. No significant alleviation (p=0.1088) in pain during intercourse was observed following treatment. Eight patients experienced a symptomatic response, while 3 exhibited no improvements in symptoms. No adverse reactions or worsening of reported symptoms was reported. CONCLUSION: The results suggest that PDT is of value in the management of vulvodynia, most probably as a viable option to conventional approaches. Further studies involving larger numbers of patients are required to confirm the efficacy of PDT in the management of vulvodynia.
LanguageEnglish
Pages645-653
JournalJournal of Reproductive Medicine
Volume52
Issue number7
Publication statusPublished - 2007

Fingerprint

Vulvodynia
Aminolevulinic Acid
Photochemotherapy
Light
Ultraviolet Rays
Lighting
Fluorescence
Pain
Therapeutics

Cite this

Zawislak, A. A., McCarron, P. A., McCluggage, W. G., Donnelly, R. F., Price, J. H., McClelland, H. R., & Woolfson, A. D. (2007). Novel bioadhesive patch-type system for photodynamic vulvodynia therapy after delivery of 5-aminolevulinic acid - Preliminary evaluation. Journal of Reproductive Medicine, 52(7), 645-653.
Zawislak, A. A. ; McCarron, P. A. ; McCluggage, W. G. ; Donnelly, R. F. ; Price, J. H. ; McClelland, H. R. ; Woolfson, A. D. / Novel bioadhesive patch-type system for photodynamic vulvodynia therapy after delivery of 5-aminolevulinic acid - Preliminary evaluation. In: Journal of Reproductive Medicine. 2007 ; Vol. 52, No. 7. pp. 645-653.
@article{00b78d6eef1a4f89b949822989b1c9e3,
title = "Novel bioadhesive patch-type system for photodynamic vulvodynia therapy after delivery of 5-aminolevulinic acid - Preliminary evaluation",
abstract = "OBJECTIVE: To assess the applicability of photodynamic therapy (PDT) in the management of vulvodynia whereby a novel, patch-type system, loaded with 5-aminolevulinic acid (ALA), was used to administer PDT to vulvar regions displaying the characteristics of vulvodynia. STUDY DESIGN: Eleven patients underwent PDT using a bioadhesive patch to deliver ALA over 4 hours. A nonlaser light source delivered 100 1 cm(-2) to the target area using red light of 630 nm. Fluorescence of protoporphyrin IX was observed under ultraviolet light illumination, with no significant difference found between that produced after the first and second applications of the patch. RESULTS: There was a significant reduction (p= 0.0077) in overall symptoms after completion of treatment. No significant alleviation (p=0.1088) in pain during intercourse was observed following treatment. Eight patients experienced a symptomatic response, while 3 exhibited no improvements in symptoms. No adverse reactions or worsening of reported symptoms was reported. CONCLUSION: The results suggest that PDT is of value in the management of vulvodynia, most probably as a viable option to conventional approaches. Further studies involving larger numbers of patients are required to confirm the efficacy of PDT in the management of vulvodynia.",
author = "Zawislak, {A. A.} and McCarron, {P. A.} and McCluggage, {W. G.} and Donnelly, {R. F.} and Price, {J. H.} and McClelland, {H. R.} and Woolfson, {A. D.}",
note = "PT: J; TC: 2",
year = "2007",
language = "English",
volume = "52",
pages = "645--653",
journal = "Journal of Reproductive Medicine",
issn = "0024-7758",
number = "7",

}

Zawislak, AA, McCarron, PA, McCluggage, WG, Donnelly, RF, Price, JH, McClelland, HR & Woolfson, AD 2007, 'Novel bioadhesive patch-type system for photodynamic vulvodynia therapy after delivery of 5-aminolevulinic acid - Preliminary evaluation', Journal of Reproductive Medicine, vol. 52, no. 7, pp. 645-653.

Novel bioadhesive patch-type system for photodynamic vulvodynia therapy after delivery of 5-aminolevulinic acid - Preliminary evaluation. / Zawislak, A. A.; McCarron, P. A.; McCluggage, W. G.; Donnelly, R. F.; Price, J. H.; McClelland, H. R.; Woolfson, A. D.

In: Journal of Reproductive Medicine, Vol. 52, No. 7, 2007, p. 645-653.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel bioadhesive patch-type system for photodynamic vulvodynia therapy after delivery of 5-aminolevulinic acid - Preliminary evaluation

AU - Zawislak, A. A.

AU - McCarron, P. A.

AU - McCluggage, W. G.

AU - Donnelly, R. F.

AU - Price, J. H.

AU - McClelland, H. R.

AU - Woolfson, A. D.

N1 - PT: J; TC: 2

PY - 2007

Y1 - 2007

N2 - OBJECTIVE: To assess the applicability of photodynamic therapy (PDT) in the management of vulvodynia whereby a novel, patch-type system, loaded with 5-aminolevulinic acid (ALA), was used to administer PDT to vulvar regions displaying the characteristics of vulvodynia. STUDY DESIGN: Eleven patients underwent PDT using a bioadhesive patch to deliver ALA over 4 hours. A nonlaser light source delivered 100 1 cm(-2) to the target area using red light of 630 nm. Fluorescence of protoporphyrin IX was observed under ultraviolet light illumination, with no significant difference found between that produced after the first and second applications of the patch. RESULTS: There was a significant reduction (p= 0.0077) in overall symptoms after completion of treatment. No significant alleviation (p=0.1088) in pain during intercourse was observed following treatment. Eight patients experienced a symptomatic response, while 3 exhibited no improvements in symptoms. No adverse reactions or worsening of reported symptoms was reported. CONCLUSION: The results suggest that PDT is of value in the management of vulvodynia, most probably as a viable option to conventional approaches. Further studies involving larger numbers of patients are required to confirm the efficacy of PDT in the management of vulvodynia.

AB - OBJECTIVE: To assess the applicability of photodynamic therapy (PDT) in the management of vulvodynia whereby a novel, patch-type system, loaded with 5-aminolevulinic acid (ALA), was used to administer PDT to vulvar regions displaying the characteristics of vulvodynia. STUDY DESIGN: Eleven patients underwent PDT using a bioadhesive patch to deliver ALA over 4 hours. A nonlaser light source delivered 100 1 cm(-2) to the target area using red light of 630 nm. Fluorescence of protoporphyrin IX was observed under ultraviolet light illumination, with no significant difference found between that produced after the first and second applications of the patch. RESULTS: There was a significant reduction (p= 0.0077) in overall symptoms after completion of treatment. No significant alleviation (p=0.1088) in pain during intercourse was observed following treatment. Eight patients experienced a symptomatic response, while 3 exhibited no improvements in symptoms. No adverse reactions or worsening of reported symptoms was reported. CONCLUSION: The results suggest that PDT is of value in the management of vulvodynia, most probably as a viable option to conventional approaches. Further studies involving larger numbers of patients are required to confirm the efficacy of PDT in the management of vulvodynia.

M3 - Article

VL - 52

SP - 645

EP - 653

JO - Journal of Reproductive Medicine

T2 - Journal of Reproductive Medicine

JF - Journal of Reproductive Medicine

SN - 0024-7758

IS - 7

ER -